Get started
Work

Abstract PS5-01-30: Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC): Final analysis from DESTINY-Breast03

Year: 2026
Type: conference-abstract
DOI: 10.1158/1557-3265.sabcs25-ps5-01-30
Authors: S.-A. Im, J. Cortes, S.-B. Kim, G. Curigliano, G. Buscacio de Sousa, S. E. Nagai, T. Sun, J. Ignacio Delgado Mingorance, V. Kaklamani, F. Puglisi, C. Levy, H. Iwata, S. A. Hurvitz, S. Nakatani, Z. Liang, S. Ashfaque, A. Egorov, E. P. Hamilton
Institutions: Seoul National University, Seoul National University Hospital, IDCQ Hospitales y Sanidad, S.L.U., Asan Medical Center, University of Ulsan, University of Milan, European Institute of Oncology, Saitama Cancer Center, Dalian University of Technology, Liaoning Cancer Hospital & Institute, University of Udine, Centro di Riferimento Oncologico, Centre François Baclesse, Nagoya City University, University of Washington, Fred Hutch Cancer Center, Daiichi-Sankyo (Japan), Daiichi Sankyo (United States), Sarah Cannon
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: closed
OpenAlex ID: W7129765535
Cites:
Cited by: 1
Related to: